Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Optimer Pharmaceuticals and Astellas Pharma have signed an exclusive collaboration and license agreement to develop and commercialize fidaxomicin tablets for the treatment of Clostridium difficile Infection (CDI) in Japan.
Subscribe to our email newsletter
Optimer is eligible to receive a one-time, up-front cash payment of $20m and additional cash payments of up to $70m upon the achievement of certain regulatory and commercial milestones from Astellas.
As per the agreement, Optimer is entitled to receive payments from Astellas that provide a return resulting in a double digit percent of Astellas net sales in the territory.
Astellas will be responsible for all future costs associated with the development and commercialization of fidaxomicin in Japan.
Fidaxomicin is approved by the FDA for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age or older in the US under the trade name DIFICID.
Astellas president and CEO Yoshihiko Hatanaka said fidaxomicin’s highly differentiated clinical profile has the potential to provide a new treatment option for patients in Japan.